7月22日,金斯瑞生物科技盘初涨超8%,预计上半年扭亏为盈最多录得逾2亿美元利润。
消息面上,公司公告,截至2025年6月30日止六个月,集团预计除税前利润较上期显著增加,其中不包括报告期内应占传奇生物科技股份有限公司的损益;及因传奇于2024年10月18日从集团解除合并带来的上期已终止经营业务亏损。经调整,集团预计报告期内录得约1.754亿美元至2.046亿美元的除税前利润,而集团上期的除税前亏损约为1.279亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.